Aminoglycoside-Induced Hearing Loss Panel
Label Mnemonic: MTRNR1
Epic code: LAB7325
Downtime form: Doctor/Provider Orders - Pathology Core and Specialty Care Nursery
Commercial Mailout Laboratory
6240-8 RCP
356-8593
Specimen(s):
Whole Blood, Saliva, or Buccal Swabs
Specimen Instructions:
Must include the following information:

  • Patient identifiers (full name, date of birth, sex and medical record number)
  • Pertinent history and clinical findings
  • Date of collection & sample type
  • Ordering physician

Samples may be refrigerated if delivery is delayed.
Collection Medium:
and
Pink top tube 6 mL (K2-EDTA) Pink top tube 6 mL (K2-EDTA)
Minimum:
Blood: 3-5cc EDTA Whole Blood- room temp
Saliva: DNA Genotek, ORAGene Discover, OGR-500
Buccal Swabs: DNA Genotek, OraCollect, OCD-100, at least 4 swabs
Delivery Instructions:
Samples accepted Monday-Friday.
Turn Around Time:
3 weeks
Reference Range:
None detected
Interpretive Data:
  • The Aminoglycoside-Induced Hearing Loss Panel (MT-RNR1 gene) include the 3 high risk variants in MT-RNR1 associated with aminoglycoside induced hearing loss according to the Clinical Pharmacogenetics Implementation Consortium (CPIC) (m.1095T>C, m.1494C>T, and m.1555A>G).
  • Aminoglycosides are widely used antibiotics known to have side effects including a risk of hearing loss. Individuals carrying one of three high risk variants in MT-RNR1 have an increased risk of aminoglycoside-induced hearing loss.
  • CPIC guideline recommends individuals with the high-risk MT-RNR1 variants should “avoid aminoglycosides unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available”.
  • The MT-RNR1 gene, including the above risk variants, is also included in our OtoSCOPE v9 panel.

Sensitivity is greater than 99%.
Comments:
Please print, complete and submit the Hearing Loss Testing Requisition Form from the Molecular Otolaryngology & Renal Research Laboratories, to Specimen Control/Mailouts with the specimen and the Epic Requisition.
Methodology:
Direct sequence analysis of the MT-RNR1 risk associated variants: m.1095T>C, m.1494C>T, and m.1555A>G.
CPT Code:
81401